Lexaria Bioscience Corp. has expanded its intellectual property portfolio with six newly granted patents, bringing the company's global total to 60 valid patents across major pharmaceutical markets. The Nasdaq-listed drug delivery innovator announced the milestone as part of its ongoing strategy to build a diverse and robust patent foundation for its DehydraTECH technology platform.
The new patents strengthen Lexaria's position in several therapeutic areas. In its patent Family #20, focused on compositions and methods for sublingual delivery of nicotine, the company received its first Australian patent, adding to existing protections in the United States, Canada, and Japan. For patent Family #21, covering compositions and methods for treating hypertension, Lexaria secured its first European Union patent, a significant development given Europe represents the world's second-largest hypertension market after the United States.
Further expansion occurred in patent Family #24, related to epilepsy treatments, where Lexaria obtained two new Australian patents and one European Union patent. This brings the company's intellectual property in this family to six U.S. patents, four Australian patents, and one European Union patent. In patent Family #27, addressing diabetes treatments, Lexaria received one new U.S. patent, bringing its total in this family to two U.S. patents. The company noted this expansion is particularly important given recent successes in the GLP-1 sector.
Lexaria's patent strategy follows a rigorous scientific process where initial hypotheses are evaluated through existing research, followed by animal and human testing to generate data supporting patent applications. The company emphasizes that granted patents provide the security needed to pursue commercial relationships for its innovations. More information about the company's technology and research can be found at www.lexariabioscience.com.
Separately, Lexaria reminded shareholders to vote in the company's upcoming annual meeting scheduled for January 27, 2026. Stockholders holding common stock as of December 1, 2025, are entitled to vote, regardless of subsequent share sales. The company encourages shareholders to review proxy materials available online at www.colonialstock.com/LEXX2026 and cast votes before the January 26, 2026, deadline. The board recommends voting for all proposals.
The expansion of Lexaria's patent portfolio to 60 granted patents worldwide represents a significant competitive advantage in the pharmaceutical technology sector. For business leaders and technology investors, this development signals Lexaria's growing intellectual property moat around its drug delivery platform, potentially increasing the company's valuation and partnership opportunities. The geographic expansion into key markets like Europe and Australia provides broader protection for technologies addressing major health conditions affecting millions globally, potentially accelerating adoption of more effective drug delivery methods across multiple therapeutic areas.
